Table 2.
Anticancer functions | Functional components | Aims and advantages | Refs |
---|---|---|---|
Bypassing biological barriers | |||
Reduced immune recognition and RES clearance | Low-protein-adsorption peptides or polysaccharides; anti-phagocytosis peptides; blood cell membranes; albumin; DNA tetrahedron; ferritin | Prolonged circulation time and evasion of liver and spleen capture | 34,90,175,177,233,234 |
Enhanced extravasation | Albumin; leucocyte membranes; rod-like nanostructures | High intratumoural delivery efficiency; high exposure of functional elements to molecular targets; microenvironmental trigger | 44,146,175 |
Enhanced tumour tissue penetration | Albumin; stroma-targeted ligands; cell-penetrating peptides | Treatment of less accessible tumour cells deep within tumour tissue | 16,177 |
Delivery across the blood–brain barrier | Albumin; DNA tetrahedron; brain-targeted peptides | Treatment of brain tumours with intravenously delivered formulations | 27,175 |
Delivery across the air–blood barrier | Albumin | Facilitated pulmonary delivery of agents to treat lung cancer | 178 |
Delivery across the intestinal endothelium | Chitosan surface coating; endothelium-penetrating ligands | Treatment of intestinal gut tumours; orally administered chemotherapy | 49,61,65,235 |
Tumour-targeted delivery | |||
Ligand-receptor recognition | Aptamers; albumin; peptides; folic acid; ferritin | Selective drug delivery to and accumulation in specific tissues, cells or subcellular organelles | 18,58,67,88,90,91,99,150,177,179,233,234 |
Protein corona manipulation | Adsorbed serum proteins | 27 | |
Stimuli responsiveness | |||
Stimuli-triggered decomposition of nanostructures | Protonable polysaccharides and peptides (pH); enzyme-cleavable peptides (tumour-specific enzymes); temperature-sensitive peptides (heat); disulfide bonds (GSH); irradiation-sensitive bonds (external light or radioactive irradiation); DNA nanoflower (H2O2); DNA nanohydrogel (pH); spherical nucleic acid (GSH); DNA origami (GSH); quantum dot DNA hydrogels (DNase); DNA coordination polymer (pH); albumin (H2O2); ferritin (pH); GroEL (ATP) | Rapid and complete drug release from otherwise stable nanostructures; selective drug release in desired location | 16,59,63,93,157,216,234 |
Stimuli-triggered (in situ) self-assembly (including gel formation) of nanostructures | Albumin; stimuli-responsive peptides | Delivery of nanostructures not suitable for administration in the assembled form owing to size, shape or mechanical properties | 148,150,179 |
Stimuli-triggered shape transformation of nanostructures | Peptide assembly; DNA origami (protein); DNA nanosuitcase (mRNA); DNA clamp (antibody); GroEL (ATP) | Rapid and complete drug release from otherwise stable nanostructures; selective drug release in desired location | 3,95,96,99,150,216,217 |
Stimuli-triggered activation and shedding of targeting, therapeutic or imaging functionality of nanostructures | Aptamer; ferritin; enzyme-cleavable peptides; breakable bonds | Minimization of non-specific nano–bio interactions; imaging signal detection during delivery; selective drug release in desired location | 55,88,191 |
Stimuli-triggered surface transformation (for example, charge reverse) of nanostructures | Protonable peptides and polysaccharides | Selective alteration of surface charge or functional groups at the tumour site to facilitate cell penetration, lysosome escape or other biological effects | 57 |
Anticancer drug building blocks | |||
Targeting ligand | Antibodies; therapeutic peptides and aptamers | Low metabolic burden and minimal adverse effects | 127,157,196,197,202 |
Self-assembly material | Therapeutic peptides and aptamers, CpG DNA nanococoon, DNA–RNA nanocapsules, plant viral nanoparticles, protozoa protein, E2 subunit of pyruvate dehydrogenase | ||
Combinatorial therapy | |||
Multidrug loading | Albumin; DNA origami; amphiphilic polysaccharides; amphiphilic peptides | Combined advantages of multiple drugs or therapeutic modalities; mechanism-based cooperation to improve tumour sensitivity to other treatment and to overcome resistance or to prevent recurrence | 18,57,63,175,178 |
Cooperation with immunotherapy | Immune cell-targeting ligands; DNA nanohydrogel; DNA–RNA nanocapsules; ferritin; hepatitis B core protein | 127,185,192 | |
Cooperation with phototherapy or radiotherapy | DNA coordination polymer; albumin; nanostructures containing sensitizer or anti-angiogenetic drug | 67,93,176 | |
Theranostics | |||
Simultaneous imaging and treatment of tumour tissue | Nanostructures containing fluorophores; magnetic nanoparticles or other imaging agents | Simultaneous diagnosis of hidden tumours or small metastasis | 91,148 |
Real-time monitoring of drug release and activity | Separable fluorophore–quencher pairs; fluorescent molecules with stimuli-dependent emission properties | Monitoring of in vivo activity of nanostructures or tumoural response to delivered drug | 148 |
CpG, cytosine-phosphate–guanine; GSH, glutathione; RES, reticuloendothelial system.